Medicated Elders, Neglected Youth: The Changing Face of Obesity

Key Takeaway: A large-scale analysis of nearly one million adults from 7 countries between 1990 and 2024 reveals that due to the widespread use of antihypertensive and cholesterol-lowering medications, the gap in blood pressure and non-HDL cholesterol between individuals with obesity over age 40 and their normal-weight peers has closed. In some countries, these parameters in older adults with obesity have even improved beyond those of their normal-weight counterparts. In contrast, younger adults with obesity under 40, who receive almost no drug therapy, continue to carry the full burden of high blood pressure and cholesterol.

A Closing Gap in Older Adults, A Persistent Risk in the Young

A familiar clinical picture is changing: an obese patient in their 60s, with a BMI over 30, may now have a blood pressure and lipid panel similar to—or sometimes even better than—their normal-weight neighbor, thanks to intensive pharmacological therapy. This massive epidemiological study published in The Lancet clearly demonstrates how effective aggressive hypertension and cholesterol management has been over the last three decades in controlling two primary mediators of cardiovascular risk (blood pressure and non-HDL cholesterol) in the older population with obesity^[1].

However, the study’s most striking and alarming aspect from a public health perspective lies elsewhere: this positive convergence is not occurring in young adults under 40. The young population with obesity, largely unmedicated, is left to manage high blood pressure and cholesterol levels on their own, continuing to bear the full burden of cardiovascular risk.

Study Methodology

An international research team pooled data from 110 population-based health surveys across seven countries, spanning over three decades from 1990 to 2024. The combined dataset included an astonishing 978,425 adults, a sample size that lends significant statistical power to the findings. The researchers compared trends in systolic blood pressure, non-HDL cholesterol (a broad measure of atherogenic lipids that includes LDL and VLDL cholesterol), and the use of antihypertensive and lipid-lowering medications over time across body mass index categories and age groups^[1].

Findings

Among adults over 40, the difference in blood pressure and non-HDL cholesterol between individuals with obesity and those with a normal BMI has narrowed dramatically over the past three decades. In some countries, older adults with obesity now have cardiovascular risk profiles that are similar to, or on paper even better than, their leaner peers. The explanation is clear: the use of antihypertensive and lipid-lowering drugs, primarily statins, has surged among older adults with obesity, far exceeding the rate of use in the normal-weight population. The medications are working. Blood pressure drops. LDL cholesterol decreases. The numbers converge.

But here is the finding that should set off alarm bells in every public health institution: this convergence was not observed in adults under the age of 40. Young adults with obesity consistently exhibited higher blood pressure and cholesterol than their normal-weight peers, with almost no increase in pharmacological treatment over the study period. This group is aging toward cardiovascular disease metabolically unprotected, pharmacologically neglected, and without a safety net.

Biological Mechanisms: Why the Findings Matter

To understand why these findings are so critical, one must consider what obesity does to the cardiovascular system at a cellular level. Excess visceral adipose tissue is not an inert storage depot; it is an active endocrine organ that secretes inflammatory cytokines like interleukin-6 and tumor necrosis factor-alpha, triggering a state of chronic, low-grade systemic inflammation^[2]. This inflammation damages the vascular endothelium, the delicate inner lining of blood vessels, and promotes atherosclerosis (hardening of the arteries) long before a heart attack or stroke occurs^[3].

Obesity also activates the renin-angiotensin-aldosterone system (RAAS), a hormonal cascade that raises blood pressure by promoting sodium retention and vasoconstriction (the narrowing of blood vessels)^[4]. Concurrently, excess adiposity leads to insulin resistance, which disrupts the liver’s lipid metabolism, causing increased VLDL production and, consequently, elevated levels of circulating non-HDL cholesterol^[5].

Statins and antihypertensives target the consequences of the process; they lower the measurable numbers. However, they do not reverse the underlying inflammatory environment, insulin resistance, the mechanical stress of excess weight on the heart, or the prothrombotic (clot-promoting) state that obesity fosters. The underlying disease process continues. The numbers improve, but the pathology may not heal at the same rate. Nevertheless, the benefit of these medications is substantial, and they fulfill a protective function for older patients with obesity. As seen in this study’s results, it is significant that older patients with obesity show the same or even a lower risk profile than their leaner counterparts.

The situation for young adults is different and more serious. Atherosclerosis is a cumulative process. Landmark autopsy studies from decades ago revealed that fatty streaks, the earliest precursors to atherosclerotic plaques, are present in the coronary arteries of young adults, and their severity correlates with the same risk factors we measure in older populations: high blood pressure, dyslipidemia, and obesity^[6]. Every year of uncontrolled exposure in a 25-year-old represents a year of plaque accumulation that no future statin prescription can fully reverse.

Conclusion: Implications for the Future

This study delivers two critical messages, both of which demand action.

First, for older adults with obesity whose blood pressure and cholesterol levels appear reassuringly normal on medication: the drugs are essential and lifesaving. Behavioral interventions for obesity, dietary modification, and, where appropriate, newer pharmacotherapies like GLP-1 receptor agonists may also be recommended. In this context, I would like to draw attention to the obesity paradox. Particularly for individuals over 65, or even 70, the treatment of obesity has specific considerations. For this age group, it may be more appropriate to recommend GLP-1 receptor agonists for those with a body mass index over 35, unless a specific indication exists.

Second, and more urgently: the medical community is failing young adults with obesity. Current clinical guidelines often reserve pharmacotherapy for individuals whose ten-year cardiovascular risk exceeds certain thresholds—thresholds that young adults rarely meet simply due to their age, regardless of how metabolically unhealthy they are^[7]. This study suggests that risk-scoring systems calibrated to short-term outcomes systematically underestimate the lifetime danger faced by a 30-year-old with untreated hypertension and dyslipidemia driven by obesity.

The policy implications are significant. Screening programs, insurance coverage for obesity treatments, and clinical guidelines must all confront the fact that young adults with obesity represent a ticking cardiovascular time bomb that current systems fail to defuse.

Study Limitations

This analysis, while vast in scope, relies on repeated cross-sectional surveys rather than following the same individuals over time, which limits its ability to draw direct causal conclusions. The seven countries studied may not be representative of global trends, especially in low- and middle-income countries where access to medication can differ significantly. Furthermore, the study focused on blood pressure and cholesterol; it did not capture other obesity-related risks such as heart failure, kidney disease, or the inflammatory burden that medications do not fully address. A single study, no matter how large, does not change everything; but it should change the conversation.

Scientific Sources

1. Metabolic traits in obesity and normal BMI in industrialised countries: a multi-country analysis of national population-based studies. Lancet (London, England). 2026;408(10552):325-347. PubMed: https://pubmed.ncbi.nlm.nih.gov/42385750/
2. Hotamisligil GS. Inflammation and metabolic disorders. Nature. 2006. DOI: 10.1038/nature05485
3. Ross R. Atherosclerosis — an inflammatory disease. N Engl J Med. 1999. DOI: 10.1056/NEJM199901143400207
4. Hall JE, et al. Obesity-induced hypertension: interaction of neurohumoral and renal mechanisms. Circ Res. 2015. DOI: 10.1161/CIRCRESAHA.116.305697
5. Ginsberg HN, et al. Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res. 2005. DOI: 10.1016/j.arcmed.2005.01.005
6. Berenson GS, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med. 1998. DOI: 10.1056/NEJM199806043382302
7. Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol. J Am Coll Cardiol. 2019. DOI: 10.1016/j.jacc.2018.11.003